Decoy Therapeutics Inc. (DCOY) stock
DCOYNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.87−0.01 (-1.13%)
Close on Nov 19, 2026Market cap $570.08KP/E –Yield –
Decoy Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Decoy Therapeutics's free cash flow for the twelve months ending Dec 31, 2018 was $4.18M. For fiscal 2025 it was -$5.40M. The highest annual figure on record is $4.18M in fiscal 2018.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$5.40M | – |
| FY2024 | Dec 31, 2024 | -$4.53M | – |
| FY2021 | Dec 31, 2021 | -$10.20M | – |
| FY2020 | Dec 31, 2020 | -$10.31M | – |
| FY2019 | Dec 31, 2019 | -$11.58M | -377.2% |
| FY2018 | Dec 31, 2018 | $4.18M | – |
| FY2017 | Dec 31, 2017 | -$27.84M | – |
| FY2016 | Dec 31, 2016 | -$32.61M | – |
| FY2015 | Dec 31, 2015 | -$21.01M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2018 | Dec 31, 2018 | $387.54K | – |
| Q3 FY2018 | Sep 30, 2018 | $21.46M | – |
| Q2 FY2018 | Jun 30, 2018 | -$8.26M | – |
| Q1 FY2018 | Mar 31, 2018 | -$9.41M | – |
| Q4 FY2017 | Dec 31, 2017 | -$5.77M | – |
| Q3 FY2017 | Sep 30, 2017 | -$8.10M | – |
| Q2 FY2017 | Jun 30, 2017 | -$5.72M | – |
| Q1 FY2017 | Mar 31, 2017 | -$8.25M | – |
| Q4 FY2016 | Dec 31, 2016 | -$6.35M | – |
| Q3 FY2016 | Sep 30, 2016 | -$7.47M | – |
See a number that looks wrong?